Unassociated Document Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

Oramed Pharmaceuticals to Present

Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA

(June 5-9, New Orleans, LA)

Israel - March 25, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a

developer of oral delivery systems, announced today that it has been selected to

present the results from the study, entitled, "Open Label Study to Assess the

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Oral Insulin

Formulations in Subjects with Type 2 Diabetes (T2DM)" at the upcoming

Annual American Diabetes Association's Scientific Sessions Conference in New

Orleans. The presentation will highlight the successful results from

its oral insulin trials on type 2 diabetes patients completed in August

abstract will also be printed in the Scientific Sessions Abstract Book, the June

2009 supplement to the journal Diabetes.

is pleased to present this poster featuring the results from our phase 2A study

of ORMD-0801 on type 2 diabetes patients and to share the information with our

colleagues," said Nadav Kidron, Oramed CEO. "As we indicated at the

completion of the study, the trial demonstrated that the oral insulin capsule

had a good safety profile and was well tolerated and effective in lowering blood

glucose levels in patients with type 2 diabetes."

poster has been assigned presentation number 434-P Clinical Therapeutics/New

Technology - Insulin Delivery Systems and is available for viewing throughout

the conference. A representative of the company will be available to

answer questions on Monday, June 8 from 12-2 PM at the Morial Convention

information about the ADA and the upcoming conference, please visit

Some of the statements contained in

this press release are forward-looking statements which involve known and

unknown risks, uncertainties and other factors which may cause the actual

results, performance or achievements of the company, or industry results, to be

materially different from any future results, performance or achievements

expressed or implied by such forward looking statements, including the risks and

uncertainties related to the progress, timing, cost, and results of clinical

trials and product development programs; difficulties or delays in obtaining

regulatory approval for our product candidates; competition from other

pharmaceutical or biotechnology companies; and the company's ability to obtain

additional funding required to conduct its research, development and

commercialization activities. Please refer to the company's filings with the

Securities and Exchange Commission for a comprehensive list of risk factors that

could cause actual results, performance or achievements of the company to differ

materially from those expressed or implied in such forward looking statements.

The company undertakes no obligation to update or revise any forward-looking

and Investor Relation Contacts:

Email: Tara@oramed.com